ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,406Medicare Part D Prescriptions Filled, Including Refills

Rank: 49 out of 229

$429K Total Retail Price of All Prescriptions

Rank: 63 out of 229

262 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
62% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 262 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

18% of this provider’s 262 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

2% of this provider’s 6,803 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LISINOPRIL 469 376 1 2
PRAVASTATIN SODIUM 328 255 2 25
OMEPRAZOLE 325 266 3 4
LEVOTHYROXINE SODIUM 312 243 4 1
FUROSEMIDE 308 235 5 8
CARVEDILOL 297 255 6 31
AMLODIPINE BESYLATE 273 226 7 5
METFORMIN HCL 222 166 8 6
POTASSIUM CHLORIDE 220 187 9 18
FLUTICASONE PROPIONATE 152 135 10 23
DOXAZOSIN MESYLATE 149 141 11 50
DIOVAN 130 109 12 42
GLIMEPIRIDE 128 115 13 63
HYDROCODONE-ACETAMINOPHEN 127 80 S3 14 7
SIMVASTATIN 113 100 15 3
CLOPIDOGREL 108 98 16 44
METOPROLOL SUCCINATE 107 107 17 16
CITALOPRAM HBR 105 70 18 21
DONEPEZIL HCL 102 102 19 29
METOPROLOL TARTRATE 98 76 20 13
CRESTOR 96 84 21 30
ZOLPIDEM TARTRATE 91 56 22 20
TRAMADOL HCL 89 66 23 26
RISPERIDONE 77 77 24 95
GABAPENTIN 77 73 24 10
PANTOPRAZOLE SODIUM 76 63 26 33
TAMSULOSIN HCL 75 54 27 24
ALENDRONATE SODIUM 75 60 27 14
ETODOLAC 69 51 29 214
ADVAIR DISKUS 69 66 29 47
EVISTA 69 69 29 106
NEXIUM 67 65 32 48
PLAVIX 64 64 33 72
ATORVASTATIN CALCIUM 61 59 34 15
GLIPIZIDE 58 48 35 36
PROAIR HFA 57 45 36 38
WARFARIN SODIUM 56 44 37 17
SULFAMETHOXAZOLE-TRIMETHOPRIM 56 52 37 111
AMOXICILLIN 55 42 39 142
RANITIDINE HCL 55 33 39 32
CARTIA XT 53 41 41 288
GLIPIZIDE ER 52 39 42 81
DILTIAZEM 24HR CD 51 42 43 89
CYCLOBENZAPRINE HCL 51 34 R 43 75
SERTRALINE HCL 50 47 45 22
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.